How many drugs treat Multiple endocrine adenomas?

Drug Landscape tracks 6 marketed treatments for Multiple endocrine adenomas (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/multiple-endocrine-adenomas.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Multiple endocrine adenomas — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multiple endocrine adenomas (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Multiple endocrine adenomas, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Protonix	pantoprazole	Generic (originally Byk Gulden/Altana/Nycomed)	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1	2000-02-02
Pantoprazole Sodium	Pantoprazole Sodium	Pfizer	Proton pump inhibitor (PPI)	(H+, K+)-ATPase enzyme	2000-01-01
Aciphex	rabeprazole	Waylis	Proton Pump Inhibitor	Potassium-transporting ATPase	1999-01-01
Aciphex	Aciphex	University of Utah		Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3
Pantoprazol	Pantoprazol	Northern Orthopaedic Division, Denmark		ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1
Rabeprazol	Rabeprazol	Janssen-Cilag, S.A.		Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Multiple endocrine adenomas
Generic (originally Byk Gulden/Altana/Nycomed) · 1 drug in Multiple endocrine adenomas
Janssen-Cilag, S.A. · 1 drug in Multiple endocrine adenomas
Northern Orthopaedic Division, Denmark · 1 drug in Multiple endocrine adenomas
Pfizer · 1 drug in Multiple endocrine adenomas
University of Utah · 1 drug in Multiple endocrine adenomas
Waylis · 1 drug in Multiple endocrine adenomas

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Multiple endocrine adenomas:

Cite this brief

Drug Landscape (2026). Multiple endocrine adenomas — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/multiple-endocrine-adenomas. Accessed 2026-06-10.

Multiple endocrine adenomas full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing